Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15
Top Cited Papers
- 28 April 2017
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 356 (6336)
- https://doi.org/10.1126/science.aal3755
Abstract
Indisulam is an aryl sulfonamide drug with selective anticancer activity. Its mechanism of action and the basis for its selectivity have so far been unknown. Here we show that indisulam promotes the recruitment of RBM39 (RNA binding motif protein 39) to the CUL4-DCAF15 E3 ubiquitin ligase, leading to RBM39 polyubiquitination and proteasomal degradation. Mutations in RBM39 that prevent its recruitment to CUL4-DCAF15 increase RBM39 stability and confer resistance to indisulam’s cytotoxicity. RBM39 associates with precursor messenger RNA (pre-mRNA) splicing factors, and inactivation of RBM39 by indisulam causes aberrant pre-mRNA splicing. Many cancer cell lines derived from hematopoietic and lymphoid lineages are sensitive to indisulam, and their sensitivity correlates with DCAF15 expression levels. Two other clinically tested sulfonamides, tasisulam and chloroquinoxaline sulfonamide, share the same mechanism of action as indisulam. We propose that DCAF15 expression may be a useful biomarker to guide clinical trials of this class of drugs, which we refer to as SPLAMs (splicing inhibitor sulfonamides).Keywords
Funding Information
- Welch Foundation (I-1879)
- Damon Runyon Cancer Research Foundation (CI-68-13)
- Cancer Prevention and Research Institute of Texas (RP150596)
- Life Sciences Research Foundation
This publication has 53 references indexed in Scilit:
- TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusionsGenome Biology, 2013
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- Using transcriptome sequencing to identify mechanisms of drug action and resistanceNature Chemical Biology, 2012
- NGS QC Toolkit: A Toolkit for Quality Control of Next Generation Sequencing DataPLOS ONE, 2012
- Global Identification of Modular Cullin-RING Ligase SubstratesCell, 2011
- A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound in patients with refractory solid tumorsCancer Chemotherapy and Pharmacology, 2011
- Building ubiquitin chains: E2 enzymes at workNature Reviews Molecular Cell Biology, 2009
- Molecular architecture and assembly of the DDB1–CUL4A ubiquitin ligase machineryNature, 2006
- Function and regulation of cullin–RING ubiquitin ligasesNature Reviews Molecular Cell Biology, 2005
- An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein databaseJournal of the American Society for Mass Spectrometry, 1994